- Home
- CSBR vs CGEN Comparison
CSBR vs CGEN Comparison
Compare CSBR & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSBR
- CGEN
- Stock Information
- Founded
- CSBR 1985
- CGEN 1993
- Country
- CSBR United States
- CGEN Israel
- Employees
- CSBR N/A
- CGEN N/A
- Industry
- CSBR Biotechnology: Biological Products (No Diagnostic Substances)
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CSBR Health Care
- CGEN Health Care
- Exchange
- CSBR Nasdaq
- CGEN Nasdaq
- Market Cap
- CSBR 113.0M
- CGEN N/A
- IPO Year
- CSBR 1986
- CGEN 2000
- Fundamental
- Price
- CSBR $5.92
- CGEN $1.29
- Analyst Decision
- CSBR Strong Buy
- CGEN Strong Buy
- Analyst Count
- CSBR 1
- CGEN 1
- Target Price
- CSBR $12.00
- CGEN $4.00
- AVG Volume (30 Days)
- CSBR 42.4K
- CGEN 200.0K
- Earning Date
- CSBR 03-11-2025
- CGEN 05-19-2025
- Dividend Yield
- CSBR N/A
- CGEN N/A
- EPS Growth
- CSBR N/A
- CGEN N/A
- EPS
- CSBR 0.46
- CGEN N/A
- Revenue
- CSBR $58,591,000.00
- CGEN $27,864,000.00
- Revenue This Year
- CSBR $15.11
- CGEN $11.81
- Revenue Next Year
- CSBR $7.80
- CGEN $28.37
- P/E Ratio
- CSBR $13.01
- CGEN N/A
- Revenue Growth
- CSBR 19.03
- CGEN N/A
- 52 Week Low
- CSBR $3.60
- CGEN $1.13
- 52 Week High
- CSBR $11.99
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- CSBR 32.28
- CGEN 41.33
- Support Level
- CSBR $5.64
- CGEN $1.23
- Resistance Level
- CSBR $8.27
- CGEN $1.52
- Average True Range (ATR)
- CSBR 0.58
- CGEN 0.09
- MACD
- CSBR -0.13
- CGEN -0.01
- Stochastic Oscillator
- CSBR 10.00
- CGEN 16.22
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.